$AARD

8 stories mentioning AARDUpdated 45d ago

Every FINWIRES story that references AARD, newest first.

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) shedding 1%.The iShares Biotechnology ETF (IBB) dropped 2.4%.In corporate news, Thermo Fisher Scientific (TMO) could benefit from improving end-market conditions and recovering biotech funding, though "structural risks" may limit the company's ability to achieve its long-term organic growth aspiration, RBC Capital Markets said in a note. RBC resumed coverage of Thermo Fisher with a sector perform rating and a $490 price target. Thermo Fisher shares were down 2.3%.Aardvark Therapeutics (AARD) shares fell 32% after the firm said the US Food and Drug Administration placed a full clinical hold on its investigational new drug application for ARD-101. Morgan Stanley downgraded the stock to underweight from equalweight, and BTIG downgraded to neutral from buy.DexCom (DXCM) said Friday it has set new long-term financial goals, including organic revenue growth of more than 10% a year through 2030. Its shares climbed past 6%.ARS Pharmaceuticals (SPRY) shares fell 7% after it posted a wider Q1 loss.

$AARD$DXCM$SPRY$TMO

Wire45d ago

Top Midday Decliners

LanzaTech Global (LNZA) signed a securities purchase agreement with certain institutional investors to sell 2 million shares in a registered direct offering, targeting gross proceeds of about $20 million, the company said Friday.Shares sank 43% following an increase in intraday trading volume to almost 323,000 from a daily average of over 44,000.Aardvark Therapeutics (AARD) said the US Food and Drug Administration has placed a full clinical hold on its investigational new drug application for ARD-101, according to a company statement late Thursday.Morgan Stanley downgraded the stock to underweight from equalweight, and BTIG to neutral from buy.Shares of Aardvark slumped 31% as intraday trading volume advanced to more than 565,000 from a daily average of over 282,000.York Space Systems (YSS) reported a Q1 loss of $114.8 million, compared with a loss of $11.7 million a year earlier.Shares dropped 18%, with intraday trading volume at nearly 2.85 million, compared with a daily average of over 2.02 million.Price: $9.74, Change: $-7.41, Percent Change: -43.21%

$AARD$LNZA$YSS

Sectors45d ago

Sector Update: Healthcare Stocks Softer Friday Afternoon

Healthcare stocks declined Friday afternoon, with the NYSE Healthcare Index falling 0.9% and the State Street Healthcare Select Sector SPDR ETF (XLV) shedding 0.8%.The iShares Biotechnology ETF (IBB) dropped 2.5%.In corporate news, Aardvark Therapeutics (AARD) shares fell 31% after the firm said the US Food and Drug Administration placed a full clinical hold on its investigational new drug application for ARD-101. Morgan Stanley downgraded the stock to underweight from equalweight, and BTIG to neutral from buy.DexCom (DXCM) said Friday it has set new long-term financial goals, including organic revenue growth of more than 10% a year through 2030. Its shares climbed past 6%.ARS Pharmaceuticals (SPRY) shares fell nearly 5% after it posted a wider Q1 net loss.Alumis (ALMS) stock was down more than 5% after it reported that its Q1 revenue dropped to $1.7 million from $17.4 million a year earlier.

$AARD$ALMS$DXCM$SPRY

Sectors45d ago

Sector Update: Healthcare

$AARD

Sectors45d ago

Sector Update: Healthcare Stocks Mixed Premarket Friday

Healthcare stocks were mixed pre-bell Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) slightly advancing and iShares Biotechnology ETF (IBB) down 0.2%.Alumis (ALMS) stock was down more than 10% after the company reported that its Q1 revenue slumped to $1.7 million from $17.4 million a year earlier.ARS Pharmaceuticals (SPRY) shares were down more than 20% after the company posted a wider Q1 net loss.Aardvark Therapeutics (AARD) stock was down more than 33% after the company said the US Food and Drug Administration placed a full clinical hold on its investigational new drug application for ARD-101 to treat hyperphagia associated with Prader-Willi Syndrome.

$AARD$ALMS$IBB$SPRY$XLV

Research45d ago

BTIG Downgrades Aardvark Therapeutics to Neutral From Buy

Aardvark Therapeutics (AARD) has an average rating of overweight and mean price target of $18.45, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$AARD

Research45d ago

Morgan Stanley Downgrades Aardvark Therapeutics to Underweight From Equalweight, Cuts Price Target to $3 From $7

$AARD

Wire46d ago

Aardvark Therapeutics' Investigational New Drug Application for ARD-101 Put on Clinical Hold by FDA

Aardvark Therapeutics (AARD) said late Thursday the US Food and Drug Administration placed a full clinical hold on its investigational new drug application for ARD-101 to treat hyperphagia associated with Prader-Willi Syndrome.The hold applies to all ongoing clinical studies under the IND, the company said, adding that it is in discussions with the FDA for resolution of the clinical hold and to fix a path forward for the drug candidate.The company also plans to unblind clinical data from the HERO and OLE trials to assess the totality of efficacy and safety data, according to the company.The company said it had $91.2 million in cash and cash equivalents as of March 31, adequate to fund operations into mid-2027.

$AARD

Track with the FINWIRES app suite

FolioX

Track AARD in your portfolio

WheelAI

Analyze AARD options with the wheel strategy

StockInsider

See market sentiment on AARD